285 related articles for article (PubMed ID: 32474930)
1. Emerging roles of autophagy in hepatic tumorigenesis and therapeutic strategies in glycogen storage disease type Ia: A review.
Cho JH; Weinstein DA; Lee YM
J Inherit Metab Dis; 2021 Jan; 44(1):118-128. PubMed ID: 32474930
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage.
Cho JH; Lee YM; Starost MF; Mansfield BC; Chou JY
J Inherit Metab Dis; 2019 May; 42(3):459-469. PubMed ID: 30637773
[TBL] [Abstract][Full Text] [Related]
3. Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.
Kim GY; Lee YM; Kwon JH; Cho JH; Pan CJ; Starost MF; Mansfield BC; Chou JY
Mol Genet Metab; 2017 Mar; 120(3):229-234. PubMed ID: 28096054
[TBL] [Abstract][Full Text] [Related]
4. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.
Lee YM; Jun HS; Pan CJ; Lin SR; Wilson LH; Mansfield BC; Chou JY
Hepatology; 2012 Nov; 56(5):1719-29. PubMed ID: 22422504
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia.
Zhang L; Lee C; Arnaoutova I; Anduaga J; Starost MF; Mansfield BC; Chou JY
Biochem Biophys Res Commun; 2020 Jun; 527(3):824-830. PubMed ID: 32430177
[TBL] [Abstract][Full Text] [Related]
6. Activation of tumor-promoting pathways implicated in hepatocellular adenoma/carcinoma, a long-term complication of glycogen storage disease type Ia.
Cho JH; Lee YM; Bae SH; Chou JY
Biochem Biophys Res Commun; 2020 Jan; 522(1):1-7. PubMed ID: 31735334
[TBL] [Abstract][Full Text] [Related]
7. An evolutionary approach to optimizing glucose-6-phosphatase-α enzymatic activity for gene therapy of glycogen storage disease type Ia.
Zhang L; Cho JH; Arnaoutova I; Mansfield BC; Chou JY
J Inherit Metab Dis; 2019 May; 42(3):470-479. PubMed ID: 30714174
[TBL] [Abstract][Full Text] [Related]
8. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.
Lee YM; Pan CJ; Koeberl DD; Mansfield BC; Chou JY
Mol Genet Metab; 2013 Nov; 110(3):275-80. PubMed ID: 23856420
[TBL] [Abstract][Full Text] [Related]
9. Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy.
Brooks ED; Landau DJ; Everitt JI; Brown TT; Grady KM; Waskowicz L; Bass CR; D'Angelo J; Asfaw YG; Williams K; Kishnani PS; Koeberl DD
J Inherit Metab Dis; 2018 Nov; 41(6):965-976. PubMed ID: 30043186
[TBL] [Abstract][Full Text] [Related]
10. Hepatic glucose-6-phosphatase-α deficiency leads to metabolic reprogramming in glycogen storage disease type Ia.
Cho JH; Kim GY; Mansfield BC; Chou JY
Biochem Biophys Res Commun; 2018 Apr; 498(4):925-931. PubMed ID: 29545180
[TBL] [Abstract][Full Text] [Related]
11. Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia.
Koeberl DD; Sun BD; Damodaran TV; Brown T; Millington DS; Benjamin DK; Bird A; Schneider A; Hillman S; Jackson M; Beaty RM; Chen YT
Gene Ther; 2006 Sep; 13(17):1281-9. PubMed ID: 16672983
[TBL] [Abstract][Full Text] [Related]
12. Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR/Cas9-based gene editing.
Arnaoutova I; Zhang L; Chen HD; Mansfield BC; Chou JY
Mol Ther; 2021 Apr; 29(4):1602-1610. PubMed ID: 33359667
[TBL] [Abstract][Full Text] [Related]
13. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia.
Koeberl DD; Pinto C; Sun B; Li S; Kozink DM; Benjamin DK; Demaster AK; Kruse MA; Vaughn V; Hillman S; Bird A; Jackson M; Brown T; Kishnani PS; Chen YT
Mol Ther; 2008 Apr; 16(4):665-72. PubMed ID: 18362924
[TBL] [Abstract][Full Text] [Related]
14. Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia.
Gjorgjieva M; Calderaro J; Monteillet L; Silva M; Raffin M; Brevet M; Romestaing C; Roussel D; Zucman-Rossi J; Mithieux G; Rajas F
J Hepatol; 2018 Nov; 69(5):1074-1087. PubMed ID: 30193922
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of SIRT1 signaling underlies hepatic autophagy impairment in glycogen storage disease type Ia.
Cho JH; Kim GY; Pan CJ; Anduaga J; Choi EJ; Mansfield BC; Chou JY
PLoS Genet; 2017 May; 13(5):e1006819. PubMed ID: 28558013
[TBL] [Abstract][Full Text] [Related]
16. Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice.
Sun MS; Pan CJ; Shieh JJ; Ghosh A; Chen LY; Mansfield BC; Ward JM; Byrne BJ; Chou JY
Hum Mol Genet; 2002 Sep; 11(18):2155-64. PubMed ID: 12189168
[TBL] [Abstract][Full Text] [Related]
17. A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia.
Zhou J; Waskowicz LR; Lim A; Liao XH; Lian B; Masamune H; Refetoff S; Tran B; Koeberl DD; Yen PM
Thyroid; 2019 Aug; 29(8):1158-1167. PubMed ID: 31337282
[No Abstract] [Full Text] [Related]
18. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer.
Ghosh A; Allamarvdasht M; Pan CJ; Sun MS; Mansfield BC; Byrne BJ; Chou JY
Gene Ther; 2006 Feb; 13(4):321-9. PubMed ID: 16195703
[TBL] [Abstract][Full Text] [Related]
19. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes.
Chou JY; Jun HS; Mansfield BC
J Inherit Metab Dis; 2015 May; 38(3):511-9. PubMed ID: 25288127
[TBL] [Abstract][Full Text] [Related]
20. Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia.
Yavarow ZA; Kang HR; Waskowicz LR; Bay BH; Young SP; Yen PM; Koeberl DD
Hum Mol Genet; 2020 Jan; 29(2):286-294. PubMed ID: 31816064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
